Treatment of graft failure with fludarabine (Flu), antithymocyte globulin (ATG) and a second allogeneic stem cell transplantation (SCT).

被引：0
|
作者：
Jabbour, EJ [1 ]
Shahjahan, M [1 ]
Rondon, G [1 ]
Anderlini, P [1 ]
Giralt, S [1 ]
Couriel, DR [1 ]
Champlin, RE [1 ]
Khouri, IF [1 ]
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2734
引用
收藏
页码：767A / 767A
页数：1
相关论文
共 50 条
  • [41] Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation
    G M T Guilcher
    R Moorjani
    T H Truong
    V A Lewis
    Bone Marrow Transplantation, 2015, 50 : 455 - 456
  • [42] Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation
    Guilcher, G. M. T.
    Moorjani, R.
    Truong, T. H.
    Lewis, V. A.
    BONE MARROW TRANSPLANTATION, 2015, 50 (03) : 455 - 456
  • [43] Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin
    Krejci, M.
    Brychtova, Y.
    Doubek, M.
    Tomiska, M.
    Navratil, M.
    Racil, Z.
    Dvorakova, D.
    Horky, O.
    Lengerova, M.
    Pospisilova, S.
    Mayer, J.
    NEOPLASMA, 2011, 58 (05) : 406 - 414
  • [44] Second Allogeneic Stem-Cell Transplantation (SCT) From a Different Donor for the Treatment of Relapsed AML and MDS After a Previous Allogeneic SCT
    Shimoni, Avichai
    Shem-Tov, Noga
    Volchek, Yulia
    Yerushalmi, Ronit
    Nagler, Arnon
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S229 - S229
  • [45] Second allogeneic stem-cell transplantation (SCT) from a different donor for the treatment of relapsed AML and MDS after a previous allogeneic SCT
    Shimoni, A.
    Shem-Tov, N.
    Volchek, Y.
    Yerushalmi, R.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S248 - S249
  • [46] Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations
    Nishihori, Taiga
    Al-Kadhimi, Zaid
    Hamadani, Mehdi
    Kharfan-Dabaja, Mohamed A.
    IMMUNOTHERAPY, 2016, 8 (04) : 435 - 447
  • [47] The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation
    R Pihusch
    E Holler
    D Mühlbayer
    P Göhring
    O Stötzer
    M Pihusch
    E Hiller
    H-J Kolb
    Bone Marrow Transplantation, 2002, 30 : 347 - 354
  • [48] The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation
    Pihusch, R
    Holler, E
    Mühlbayer, D
    Göhring, P
    Stötzer, O
    Pihusch, M
    Hiller, E
    Kolb, HJ
    BONE MARROW TRANSPLANTATION, 2002, 30 (06) : 347 - 354
  • [49] Dose-intensified antithymocyte globulin (ATG) in steroid-resistant graft-versus-host disease (GVHD) after allogeneic marrow or blood stem cell transplantation.
    Kienast, J
    Ippoliti, C
    Mehra, R
    Ueno, N
    Champlin, R
    Khouri, I
    Giralt, S
    Gajewski, J
    Claxton, D
    Anderlini, P
    Andersson, B
    Przepiorka, D
    BLOOD, 1997, 90 (10) : 457 - 457
  • [50] Graft failure after allogeneic hematopoietic stem cell transplantation
    Ozdemir, Zehra Narli
    Bozdag, Sinem Civriz
    TRANSFUSION AND APHERESIS SCIENCE, 2018, 57 (02) : 163 - 167
12345